Reengineering Bone Health: Preventing Steroid-Induced Osteoporosis Without Jaw Damage

Reengineering Bone Health: Preventing Steroid-Induced Osteoporosis Without Jaw Damage

Alvin Sherman Library

Glucocorticoid ("steroid") drugs are essential for treating autoimmune diseases, but long-term use often weakens bones, leading to a condition called glucocorticoid-induced osteoporosis (GIO). In the United States, steroids such as prednisone and dexamethasone are prescribed to over 10 million patients annually, and roughly 30% of long-term users develop GIO, contributing $20-30 billion in annual health-care costs. To this end, bisphosphonates are commonly used to treat GIO by preventing bone-loss; however, they can also cause a serious adverse effect called medication-related osteonecrosis of the jaw (MRONJ). Thus, safer jaw-protective treatments are urgently needed. In this study, we tested a different strategy by targeting Piezo1, a protein that helps cells "feel" physical forces. We hypothesized that the pharmacologic activation of Piezo1 with Yoda2, a Piezo1 agonist, could ameliorate GIO without damaging the jaw. We induced osteoporosis in mice by administering dexamethasone and compared Yoda2 treatment with bisphosphonate, while jaw injury was also induced to trigger MRONJ in GIO mice. Histology, TRAP staining, and micro-CT showed results similar to those in the bisphosphonate group: Yoda2 preserved bone density, restored normal bone structure, and reduced osteoclast activity in GIO mice. Yoda2, but not bisphosphonate, boosted Type-H blood vessels that support bone repair. To confirm that Piezo1 expressed in bone cells was essential for this benefit, we repeated the experiments in mice genetically lacking Piezo1 in osteoclast cells; in these mice, Yoda2 no longer protected the skeleton. These suggest that Piezo1 activation is a promising approach to prevent GIO while avoiding devastating jaw complications of MRONJ.